BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
Flawless balance sheet and slightly overvalued.
Share Price & News
How has BioSyent's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RX exceeded the Canadian Pharmaceuticals industry which returned -61.6% over the past year.
Return vs Market: RX underperformed the Canadian Market which returned -14.9% over the past year.
Price Volatility Vs. Market
How volatile is BioSyent's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall StAre BioSyent's (CVE:RX) Statutory Earnings A Good Reflection Of Its Earnings Potential?
2 weeks ago | Simply Wall StWhat Kind Of Shareholder Owns Most BioSyent Inc. (CVE:RX) Stock?
1 month ago | Simply Wall StDoes Market Volatility Impact BioSyent Inc.'s (CVE:RX) Share Price?
Is BioSyent undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RX (CA$4.1) is trading below our estimate of fair value (CA$12.01)
Significantly Below Fair Value: RX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RX is poor value based on its PE Ratio (13.1x) compared to the Pharmaceuticals industry average (9.6x).
PE vs Market: RX is poor value based on its PE Ratio (13.1x) compared to the Canadian market (13.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RX is overvalued based on its PB Ratio (2.2x) compared to the CA Pharmaceuticals industry average (1.2x).
How is BioSyent forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RX's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if RX's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RX's revenue (14.3% per year) is forecast to grow faster than the Canadian market (5.6% per year).
High Growth Revenue: RX's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RX's Return on Equity is forecast to be high in 3 years time
How has BioSyent performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RX has high quality earnings.
Growing Profit Margin: RX's current net profit margins (20.4%) are lower than last year (26.5%).
Past Earnings Growth Analysis
Earnings Trend: RX's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: RX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RX had negative earnings growth (-23.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-23.4%).
Return on Equity
High ROE: RX's Return on Equity (16.9%) is considered low.
How is BioSyent's financial position?
Financial Position Analysis
Short Term Liabilities: RX's short term assets (CA$26.8M) exceed its short term liabilities (CA$3.4M).
Long Term Liabilities: RX's short term assets (CA$26.8M) exceed its long term liabilities (CA$1.8M).
Debt to Equity History and Analysis
Debt Level: RX is debt free.
Reducing Debt: RX had no debt 5 years ago.
Debt Coverage: RX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RX has no debt, therefore coverage of interest payments is not a concern.
What is BioSyent's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RX's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. René C. Goehrum has been the Chairman of BioSyent Inc. since June 1999 and its Chief Executive Officer since May 1999 and also its President since June 2006. Mr. Goehrum served as the President and ser ...
CEO Compensation Analysis
Compensation vs Market: René's total compensation ($USD354.15K) is above average for companies of similar size in the Canadian market ($USD155.86K).
Compensation vs Earnings: René's compensation has been consistent with company performance over the past year.
|VP of Finance & CFO||1.67yrs||CA$260.94k||0.22% CA$120.6k|
|Vice President of Corporate Development||1.67yrs||CA$244.11k||0.22% CA$119.6k|
|Vice President of Community Health Business||4.08yrs||CA$217.45k||0.46% CA$248.8k|
|Director of Medical and Regulatory Affairs||4.58yrs||CA$200.25k||no data|
|Director of Human Resources||1.33yrs||no data||0.067% CA$36.2k|
|Director of the Hospital Business Unit - Biosyent Pharma Inc||4.58yrs||CA$195.46k||0.16% CA$84.7k|
Experienced Management: RX's management team is considered experienced (2.9 years average tenure).
|Independent Director||2yrs||CA$29.90k||0.80% CA$430.5k|
|Lead Independent Director||2.33yrs||CA$29.90k||1.27% CA$688.3k|
|Independent Director||2.33yrs||CA$27.60k||0.080% CA$43.4k|
|Independent Director||2.33yrs||CA$27.60k||0.11% CA$59.4k|
|Independent Director||6.33yrs||CA$27.60k||0.011% CA$5.9k|
Experienced Board: RX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BioSyent Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioSyent Inc.
- Ticker: RX
- Exchange: TSXV
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$54.147m
- Shares outstanding: 12.86m
- Website: https://www.biosyent.com
- BioSyent Inc.
- 2476 Argentia Road
- Suite 402
- L5N 6M1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RX||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Sep 1988|
|BIOY.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Sep 1988|
BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. The company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells and is indicated for the prevention of iron deficiency anemia; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains. BioSyent Inc. sells its products number of wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Mississauga, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/28 02:59|
|End of Day Share Price||2020/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.